Pharma companies fined $4.5m over product claims

They admitted to making false or misleading representations in the marketing of two pain relief products GlaxoSmithKline Consumer Healthcare Australia and Novartis Consumer Health Australasia have been ordered to pay $4.5 million in penalties over false or misleading representations in the marketing of their Voltaren Osteo Gel and Voltaren Emulgel pain relief products. From January